Ex-'King of Biotech' set to serve four-year term for fraud
NEW YORK (Reuters) - David Blech, once dubbed the "King of Biotech", failed to persuade a U.S. appeals court to throw out his four-year prison term for securities fraud on the ground that his sentencing judge was biased.
Blech, 58, had argued in court papers that U.S. District Judge Colleen McMahon improperly considered his race and social status in imposing the sentence.
The defendant, who is white, Jewish and was once among the wealthiest Americans, said McMahon wanted to counter a view that "we let people like you get away with things that we don't let poor black drug addicts" get away with.
In an order on Tuesday, the 2nd U.S. Circuit Court of Appeals said McMahon "made a number of ill‐conceived remarks that bordered on the inappropriate," but that it was not persuaded that she sentenced Blech "based on unconstitutional factors such as race".
It said McMahon sentenced Blech based on factors including "the need for specific deterrence for a recidivist, and the need for general deterrence for those who might otherwise feel that some white‐collar crimes are 'games worth playing.'"
The court also upheld McMahon's $1.34 million forfeiture order, saying Blech waited too long to object.
Richard Levitt, a lawyer for Blech, declined to comment. The defendant had sought to be resentenced by a different judge.
Blech, who has said he has bipolar disorder, had pleaded guilty in May 2012 to manipulating shares of biopharmaceutical companies Pluristem Therapeutics Inc (PSTI.O) and Intellect Neurosciences Inc (ILNS.PK) in 2007 and 2008.
He reached a $1.03 million civil settlement last August with the U.S. Securities and Exchange Commission.
Blech had also pleaded guilty in 1998 to an unrelated fraud, but was sentenced to probation.
Earlier in his career, Blech helped found Celgene Corp (CELG.O), whose products include the blood cancer drug Revlimid, and whose market value on Friday topped $68 billion.
He also helped found Icos Corp, now part of Eli Lilly & Co (LLY.N), which developed Cialis to treat erectile dysfunction.
Forbes magazine said Blech was worth $295 million in 1992, making him among the 400 richest Americans.
Blech is housed at a low-security prison in Fort Dix, New Jersey. He is not eligible for release until March 12, 2017.
The case is U.S. v. Blech, 2nd U.S. Circuit Court of Appeals, No. 13-1881.
(Reporting by Jonathan Stempel; Editing by Stephen Powell)
- Tweet this
- Share this
- Digg this
- UPDATE 2-Concordia finally heads for scrapyard after massive salvage operation
- Seven arrests made in $1.6 million StubHub cyberfraud case |
- Facebook beats Wall Street targets, stock hits record high |
- UPDATE 3-SEC's long path to money market fund reform ends in compromise
- Two Ukrainian fighter jets shot down over rebel-held territory
India will not support a trade facilitation protocol ahead of a July 31 deadline unless its concerns about subsidies are met, two senior government officials said on Wednesday, sticking to a hard line critics say could derail a landmark global trade deal. Full Article
Bullish on Indian equities, but gains seen 'less sharp'- Goldman Sachs Full Article
Jet Airways chairman says looking to restructure debts, talking to bankers Full Article
Honda's India unit to account for 25 pct of Asia Pacific sales by March 2017 - exec Full Article